115 related articles for article (PubMed ID: 8534929)
41. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin.
Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Hamburger DR; Delauter BJ; Grim A; Zuhowski EG; Joseph E; Pluim D; Potter DM; Eiseman JL
Clin Cancer Res; 2002 Sep; 8(9):2992-9. PubMed ID: 12231546
[TBL] [Abstract][Full Text] [Related]
42. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
43. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
44. The Chinese medicine JC-001 enhances the chemosensitivity of Lewis lung tumors to cisplatin by modulating the immune response.
Chuang MH; Jan MS; Chang JT; Lu FJ
BMC Complement Altern Med; 2017 Apr; 17(1):210. PubMed ID: 28399860
[TBL] [Abstract][Full Text] [Related]
45. Antiangiogenic drugs for chemotherapy of bladder tumours.
Rocchetti R; Talevi S; Margiotta C; Calza R; Corallini A; Possati L
Chemotherapy; 2005 Oct; 51(6):291-9. PubMed ID: 16224178
[TBL] [Abstract][Full Text] [Related]
46. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy.
Seguin J; Brullé L; Boyer R; Lu YM; Ramos Romano M; Touil YS; Scherman D; Bessodes M; Mignet N; Chabot GG
Int J Pharm; 2013 Feb; 444(1-2):146-54. PubMed ID: 23380621
[TBL] [Abstract][Full Text] [Related]
47. Antitumor interaction of short-course endostatin and ionizing radiation.
Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
[TBL] [Abstract][Full Text] [Related]
48. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD
Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968
[TBL] [Abstract][Full Text] [Related]
49. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma.
Anderson IC; Shipp MA; Docherty AJ; Teicher BA
Cancer Res; 1996 Feb; 56(4):715-8. PubMed ID: 8631001
[TBL] [Abstract][Full Text] [Related]
50. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
Teicher BA; Ikebe M; Ara G; Keyes SR; Herbst RS
In Vivo; 1997; 11(6):463-72. PubMed ID: 9509296
[TBL] [Abstract][Full Text] [Related]
51. Significant inhibition of endothelial cell growth in tumor vasculature by an angiogenesis inhibitor, TNP-470 (AGM-1470).
Yamamoto T; Sudo K; Fujita T
Anticancer Res; 1994; 14(1A):1-3. PubMed ID: 7513139
[TBL] [Abstract][Full Text] [Related]
52. Captopril augments antitumor activity of cyclophosphamide in mice.
Kowalski J; Herman ZS
Pol J Pharmacol; 1996; 48(3):281-5. PubMed ID: 9112663
[TBL] [Abstract][Full Text] [Related]
53. TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy.
Teicher BA; Emi Y; Kakeji Y; Northey D
Eur J Cancer; 1996 Dec; 32A(14):2461-6. PubMed ID: 9059334
[No Abstract] [Full Text] [Related]
54. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
Fram RJ; Woda BA; Wilson JM; Robichaud N
Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
[TBL] [Abstract][Full Text] [Related]
55. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
Hanahan D; Bergers G; Bergsland E
J Clin Invest; 2000 Apr; 105(8):1045-7. PubMed ID: 10772648
[No Abstract] [Full Text] [Related]
56. Angiogenesis inhibitor TNP-470: cytotoxic effects on human neoplastic cell lines.
Sedláková O; Sedlák J; Hunáková L; Jakubíková J; Duraj J; Sulíková M; Chovancová J; Chorváth B
Neoplasma; 1999; 46(5):283-9. PubMed ID: 10665843
[TBL] [Abstract][Full Text] [Related]
57. Effect of a bovine hemoglobin preparation on the response of the FSaIIC fibrosarcoma to chemotherapeutic alkylating agents.
Teicher BA; Herman TS; Hopkins RE; Menon K
J Cancer Res Clin Oncol; 1992; 118(2):123-8. PubMed ID: 1735732
[TBL] [Abstract][Full Text] [Related]
58. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Browder T; Butterfield CE; Kräling BM; Shi B; Marshall B; O'Reilly MS; Folkman J
Cancer Res; 2000 Apr; 60(7):1878-86. PubMed ID: 10766175
[TBL] [Abstract][Full Text] [Related]
59. Toxicity of C
Prylutska S; Grynyuk I; Skaterna T; Horak I; Grebinyk A; Drobot L; Matyshevska O; Senenko A; Prylutskyy Y; Naumovets A; Ritter U; Frohme M
Arch Toxicol; 2019 May; 93(5):1213-1226. PubMed ID: 30989314
[TBL] [Abstract][Full Text] [Related]
60. Antitumor effects and hematotoxicity of C
Prylutska SV; Lynchak OV; Kostjukov VV; Evstigneev MP; Remeniak OV; Rybalchenko VK; Prylutskyy YI; Ritter U; Scharff P
Exp Oncol; 2019 Jun; 41(2):106-111. PubMed ID: 31262160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
